Johnson & Johnson Invests in China for Healthcare Innovation
The China Economic Net website reported that global healthcare giant Johnson & Johnson has vowed to further promote an innovation strategy to support China and the world to fight the pandemic and advance the development of public health. With a number of innovative products, technologies and solutions displayed on-site, the company is showing its
Comments Off on Johnson & Johnson Invests in China for Healthcare Innovation • Read this story »
More Articles
Korean Drugmakers to Seek Global Partnerships
The Korea Herald website reported that South Korean pharmaceutical companies and global drugmakers came together to discuss new business partnerships and open innovation at this year’s Korea Pharma Associations Conference in Seoul. As one of the biggest pharma industry events of the year, the conference
Comments Off on Korean Drugmakers to Seek Global Partnerships • Read this story »
Setting the Gears of Innovation in Motion
The Business Times website reported on a conference where the Research Director at Johnson & Johnson, Dr Loy Chong Jin shared how creating a collaborative business ecosystem using external innovation helped to accelerate new business opportunities. “It is all about relationship-building,” he
Comments Off on Setting the Gears of Innovation in Motion • Read this story »
Radical Experiment Changing the Way Big Pharma Innovates
The Fortune website noted that in the highly competitive, IP-obsessed world of drug development, throwing open the doors and inviting people in, is a departure in strategy to say the least. Yet, such is the surprising concept behind JLABS, the “no strings attached” incubator that Johnson & Johnson
Comments Off on Radical Experiment Changing the Way Big Pharma Innovates • Read this story »
Open Innovation and Big Pharma
The PMLive website reported that there has been a major drive towards an open innovation model among big pharma companies, seeking to forge closer ties with small biopharma companies and academic groups in recognition that relying on in-house pharma R&D is no longer enough to remain competitive.
Comments Off on Open Innovation and Big Pharma • Read this story »
Building an Open Innovation Approach to R&D
The Wall Street Journal website reported that Open Innovation (OI) is gaining an important foothold across a number of major industries, from information technology to retail. Today, health care leaders are starting to recognize that OI can have great value in research and development and in marketing
Comments Off on Building an Open Innovation Approach to R&D • Read this story »
Winners Announced in OI Mental Health Challenge
The Sacramento Bee website reported that Scientists Without Borders, a program of the New York Academy of Sciences, in collaboration with Johnson & Johnson, has announced the winners of a $10,000 open innovation challenge that called for ideas to increase awareness and utilization of mental health Comments Off on Winners Announced in OI Mental Health Challenge • Read this story »
Chesbrough on Open Innovation in Life Sciences
The journal Nature published an interview with Henry Chesbeough. The article noted that open innovation has taken the business world by storm. In his 2003 breakout book, Chesbrough argued — based largely on observations of the computer industry — that companies need to look beyond their walls
Comments Off on Chesbrough on Open Innovation in Life Sciences • Read this story »
Evotec expands open innovation push with Yale
The Pmlive website announced that Germany’s Evotec has entered into a strategic partnership with Yale University as it continues to adopt an open innovation approach to drug discovery. The latest agreement will see Evotec join forces with Yale on discovery science for a number of diseases with
Comments Off on Evotec expands open innovation push with Yale • Read this story »
Open Innovation to Fill Pharma’s Pipelines
The medcitynews website reported that open innovation and cooperation in the pharmaceutical industry will continue to gain traction as patent losses and R&D cutbacks force drug companies to look